Core Viewpoint - The company, Jiukang Biotechnology, has evolved from a代理商 to a leading player in the IVD (in vitro diagnostics) industry in China, focusing on innovation and precision diagnosis to drive future growth [2][3]. Group 1: Company Development - Jiukang Biotechnology started as an代理商 for an international IVD brand and quickly gained recognition, becoming a service supplier for the national quality control products [3]. - The company has maintained a strong client base, with over 70% of top-tier hospitals in China being loyal customers [3]. - The company has significantly increased its R&D investment, with R&D accounting for 21% of sales revenue in the first three quarters of 2025, up from 14% in the same period of 2024 [3]. Group 2: Product Innovation - R&D efforts are focused on new products in areas such as pathology, chemiluminescence, and coagulation, leading to an increase in medical device registrations and patents [4]. - The company has launched new products, including a high-speed fully automated chemiluminescence immunoassay analyzer and a biochemical analyzer, enhancing its competitive edge in the market [4]. - Jiukang's first AI project, a prostate cancer AI interpretation software, has been developed and validated, with plans to expand into smart pathology products [4]. Group 3: Strategic Partnerships - The company aims to become a platform enterprise in the IVD sector, collaborating with leading international firms to leverage their strengths and expand into global markets [5]. - A strategic partnership with Abbott began in 2013, allowing Jiukang to share its patented processes for global product production, resulting in profit-sharing [6]. - In 2020, a significant partnership with China National Pharmaceutical Group (Sinopharm) was established, enhancing sales channels and accelerating growth, with Sinopharm becoming the largest shareholder [6]. Group 4: Industry Trends - The IVD industry in China is rapidly developing, with significant growth potential driven by medical reform and innovation [7]. - The industry is expected to undergo a transformation towards high-quality upgrades, with a focus on value competition rather than price competition [7]. - Emerging technologies such as molecular diagnostics and AI-assisted diagnostics are anticipated to become core competitive advantages, with an emphasis on domestic alternatives in high-end markets [7].

截至2026年1月28日收盘，九强生物(300406)报收于13.89元，下跌2.87%，换手率2.43%，成交量10.31万 手，成交额1.44亿元。 当日关注点 交易信息汇总 资金流向 九强生物发布业绩预告，预计2025年全年扣非后净利润盈利1.71亿元至2.11亿元。九强生物发布业绩预 告，预计2025年全年归属净利润盈利1.8亿元至2.18亿元。 公司公告汇总 2025年度业绩预告 北京九强生物技术股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为18,000万 元至21,800万元，较上年同期下降66.21%至59.07%。扣除非经常性损益后的净利润预计为17,093万元至 21,093万元，同比下降67.16%至59.48%。业绩下降主要由于控股子公司美创公司受医疗行业政策影响， 拟计提商誉减值准备约1.8亿元，以及主营业务受政策影响导致盈利能力下滑。非经常性损益对净利润 的影响为707万元，主要为政府补助。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自【交易信息汇总】：1月28日主力资金净流 ...

Group 1 - The company expects a net profit attributable to shareholders of 180 million to 218 million yuan for 2025, representing a decline of 66.21% to 59.07% compared to the same period last year [1] - The net profit after deducting non-recurring gains and losses is projected to be between 170.93 million and 210.93 million yuan, reflecting a decrease of 67.16% to 59.48% year-on-year [1] - The company's subsidiary, Meichuang, is facing significant operational challenges due to the impact of medical industry policies, increased competition, and pressure on both volume and pricing [1] Group 2 - The company plans to recognize an impairment provision for goodwill of approximately 180 million yuan due to signs of impairment in related asset groups, following a cautious principle [1] - As of the date of this announcement, the goodwill impairment testing is still ongoing, and the final amount of the impairment provision will be determined based on evaluations and audits by qualified assessment and auditing institutions [1]

Group 1 - The company, Jiukang Bio, announced an expected net profit attributable to shareholders for the year 2025 to be between 180 million and 218 million yuan, representing a decline of 66.21% to 59.07% compared to the previous year's net profit of 532.6353 million yuan [1]

Core Viewpoint - Jiukang Bio (300406) has announced a significant decline in its expected net profit for 2025, projecting a decrease of 59.07% to 66.21% year-on-year [1] Financial Performance - The company expects the net profit attributable to shareholders to be between 180 million to 218 million yuan for 2025 [1] - The net profit after deducting non-recurring gains and losses is projected to be between 171 million to 211 million yuan, reflecting a year-on-year decline of 59.48% to 67.16% [1]

公告中解释本次业绩变动的原因为： 报告期内，公司所处体外诊断行业受政策影响，一方面增值税税率调整影响，另一方面业务受到医疗行 业政策影响，量价承压，公司盈利能力下滑，若不考虑商誉减值计提因素，经公司测算 2025 年度归属 于上市公司股东的净利润预计在 3.6 亿-3.98 亿之间，预计较上年同期下降 32%-25%。 1、资产减值计提 公司控股子公司美创公司受医疗行业政策影响，量价承压，行业竞争日益加剧，经营受到很大影响，出 于谨慎性原则，判断相关资产组商誉存在减值迹象，公司本期拟计提商誉减值准备约 1.8 亿元。截至本 公告披露日，相关商誉减值测试工作尚在进行中，最终商誉减值准备计提金额，将在公司聘请的具备证 券期货从业资格的评估机构及审计机构进行评估和审计的基础上，由公司履行内部的相关程序后确定。 2、主营业务影响 证券之星消息，九强生物发布业绩预告，预计2025年全年归属净利润盈利1.8亿元至2.18亿元。 公司结合自身状况和行业环境，积极发展病理产业，优化业务结构，发挥自身的技术优势，通过新产品 研发丰富自身的产品线，同时优化产品工艺，通过国产替代进口等降低成本，提升盈利能力。 3、2025 年，预 ...

智通财经APP讯，九强生物(300406.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 1.8亿元至2.18亿元，同比下降59.07%至66.21%;扣除非经常性损益后的净利润1.71亿元至2.11亿元，同比 下降59.48%至67.16%。 ...

南财智讯1月28日电，九强生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 18,000万元—21,800万元，同比预减59.07%—66.21%；预计2025年全年归属于上市公司股东的扣除非经 常性损益的净利润为17,093万元—21,093万元，同比预减59.48%—67.16%。业绩变动原因说明：1、资 产减值计提：公司控股子公司美创公司受医疗行业政策影响，量价承压，行业竞争日益加剧，经营受到 很大影响，出于谨慎性原则，判断相关资产组商誉存在减值迹象，公司本期拟计提商誉减值准备约1.8 亿元。截至本公告披露日，相关商誉减值测试工作尚在进行中，最终商誉减值准备计提金额，将在公司 聘请的具备证券期货从业资格的评估机构及审计机构进行评估和审计的基础上，由公司履行内部的相关 程序后确定。2、主营业务影响：报告期内，公司所处体外诊断行业受政策影响，一方面增值税税率调 整影响，另一方面业务受到医疗行业政策影响，量价承压，公司盈利能力下滑，若不考虑商誉减值计提 因素，经公司测算2025年度归属于上市公司股东的净利润预计在3.6亿-3.98亿之间，预计较上年同期下 降32%—25%。公司结合自身状况 ...

九强生物公告，预计2025年度净利润为1.8亿元至2.18亿元，同比下降59.07%-66.21%。预计扣除非经常 性损益后的净利润为1.71亿元至2.11亿元，同比下降59.48%-67.16%。业绩变动主要由于资产减值计提和 主营业务受到医疗行业政策影响。 ...

证券代码：300406 证券简称：九强生物 公告编号：2026- 006 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | | | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 | 比上年同期 | 18,000 | ～ | 21,800 | 53,263.53 | | 东的净利润 | 下降 | 66.21% | ～ | 59.07% | | | 扣除非经常性损益 | | 17,093 | ～ | 21,093 | | | 后的净利润 | 比上年同期 下降 | 67.16% | ～ | 59.48% | 52,055.95 | 二、与会计师事务所沟通情况 本 ...